CSI Market
Sign In | Register

Matinas Biopharma Holdings Inc (MTNB) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access MTNB Annual Cash Flow →
Observing cash flow movements over recent quarters helps explain how Matinas Biopharma Holdings Inc adapts cash usage as operating conditions change.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Jun 30 2026)
6 Months 		(Mar 31 2026) (Dec 31 2025) (Sep 30 2025) (Jun 30 2025)
Operating Activities
Income-3.25
Depreciation & amortization0.00
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Impairment of Intangible Assets, Finite-lived0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets, Total-0.14
Share-based Compensation0.22
Income (Loss) from Equity Method Investments0.00
Debt Instrument, Convertible, Beneficial Conversion Feature0.00
Notepayableforinsurancepremiums-
Operating Lease Impairment Loss-
Finance Lease Right Of Use Asset Amortization-
Deferred Tax Liability-
Gain Loss On Change In Fair Value Of Warrant Liability-
Increase Decrease In Operating Lease Liability-0.17
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Accounts Receivable0.00
Increase (Decrease) in Accounts Payable0.53
Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities0.05
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets0.31
Other Working Capital0.00
Other Noncash Expense0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities-1.16
Discontinued operations0.00
Net Cash flow from Operating Activities-3.44
Investing Activities
Capital Expenditures0.00
Sale of Capital Items0.00
Proceeds from Sale and Maturity of Marketable Securities0.00
Payments to Acquire Marketable Securities0.00
Real Estate Investments0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities0.00
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.00
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.00
Payments For Return Of Membership Capital-
Payments Of Preferred Stock Issuance Costs-
Proceeds From Issuance Of Holdings Common Stock-
Proceeds From Formation Of Warrants-
Proceeds From Repayments Of Longterm Capital Lease Obligations-
Net Proceeds From Atm Sales-
Common Stock Issuance Cost-
Net Proceeds From Sales-
Warrant Tender Issuance Cost-
Net Proceeds From A T M Sales-
Finance Lease Principal Payments-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities0.00
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-3.44
Total Cash Flow-3.44
4 historic quarters locked

Sign in to unlock the full Matinas Biopharma Holdings Inc cash flow history.

Sign In Create Free Account

About Matinas Biopharma Holdings Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

  • Form: 10-Q (Period: 20260630)
  • Filed with the SEC: August 13, 2026
  • Source: form10-q.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001493152-26-037748

Figures are derived from filed reports and may be restated. Historical data is subject to revision.